Key result
Novel cancer agents show promise for improving survival rates and addressing the global cancer burden.
May support expanded trials of novel agents; leaves open practice change pending randomized survival data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zakharenko et al. (2026) studied this question. Novel oncological drugs and new agents are the focus of this special issue addressing cancer, the second leading cause of death worldwide after cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: